Frontiers in Medicine | |
Complement, a Therapeutic Target in Diabetic Kidney Disease | |
article | |
Kelly Budge1  Sergio Dellepiane1  Samuel Mon-Wei Yu1  Paolo Cravedi1  | |
[1] Department of Medicine, Icahn School of Medicine at Mount Sinai, United States | |
关键词: diabetes; diabetic kidney disease; C3a; complement; glomerulosclerosis; MAC; C5a; | |
DOI : 10.3389/fmed.2020.599236 | |
学科分类:社会科学、人文和艺术(综合) | |
来源: Frontiers | |
【 摘 要 】
Currently available treatments of diabetic kidney disease (DKD) remain limited despite improved understanding of DKD pathophysiology. The complement system is a central part of innate immunity, but its dysregulated activation is detrimental and results in systemic diseases with overt inflammation. Growing evidence suggests complement activation in DKD. With existent drugs and clinical success of treating other kidney diseases, complement inhibition has emerged as a potential novel therapy to halt the progression of DKD. This article will review DKD, the complement system's role in diabetic and non-diabetic disease, and the potential benefits of complement targeting therapies especially for DKD patients.
【 授权许可】
CC BY
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202108180002603ZK.pdf | 1376KB | download |